Celcuity Q2 net loss $14.6M; Phase 1b gedatolisib data shows 48.6-month median PFS

Celcuity Inc.

2023-Q2 EPS reported -$1.22

Net loss $14.6M ($0.66/share) vs $10.0M ($0.67) Q2 2022; non-GAAP adjusted net loss $12.8M.
Cash, equivalents and short-term investments $146.2M at June 30; R&D $13.7M, up $5.4M on VIKTORIA-1.
Phase 3 VIKTORIA-1 on track; recruiting at ~200 sites in 20 countries; PIK3CA wild-type data H2 2024, mutant H1 2025.
Updated Phase 1b gedatolisib combo: median PFS 48.6 months, ORR 79% in 41 treatment-naïve HR+/HER2- advanced breast cancer patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Celcuity Inc. reported second quarter ended June 30, 2023 results: net income $14.6 million, or $0.66 loss per share, EPS $0.66 loss per share.

Period: second quarter ended June 30, 2023
Net income: $14.6 million, or $0.66 loss per share
EPS: $0.66 loss per share
Result: reported results

Exact text from the filing

Net loss for the second quarter of 2023 was $14.6 million, or $0.66 loss per share, compared to a net loss of $10.0 million, or $0.67 loss per share, for the second quarter of 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Celcuity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-027544

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.